Article
Current presbyopia-correcting technology good despite limited accommodative power
FDA approval of the crystalens (eyeonics), in addition to the AcrySof ReSTOR (Alcon Laboratories) and ReZoom multifocal (AMO) IOLs, allows ophthalmologists the ability to offer various choices of presbyopia-correcting technology with the hope of providing a surgical procedure that will greatly reduce or eliminate their patients' dependence on glasses following cataract surgery and refractive lens exchange. Hype and rumor regarding accommodating lens technology has created confusion regarding just how effective or ineffective these particular lenses may be. A review of the results in peer-reviewed medical literature in addition to an analysis of theoretical considerations with regard to the limits of accommodation provided by these lenses should clarify their ultimate usefulness in the average ophthalmic practice.
Single-optic IOLs
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
